Clinical Trials/JPRN-UMIN000014775

JPRN-UMIN000014775

Completed

未知

Effect of Ipragliflozin, a new oral hypoglycemic agent, on body composition in patients with diabetes - Effect of Ipragliflozin on body composition

Keio University School of Medicine, Internal Medicine0 sites30 target enrollmentAugust 15, 2014

Conditionstype 2 diabetes

Overview

Phase: 未知
Intervention: Not specified
Conditions: type 2 diabetes
Sponsor: Keio University School of Medicine, Internal Medicine
Enrollment: 30
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

August 15, 2014

End Date

March 27, 2017

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Keio University School of Medicine, Internal Medicine

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Contraindication for Ipragliflozin Patients who had been treated with metformin or GLP\-1 analogues Pregnant woman

Outcomes

Primary Outcomes

Not specified

Similar Trials

Efficacy of ipragliflozin on glucose metabolismtype 2 diabetes mellitus

JPRN-UMIN000013921Shiraiwa Medical Clinic10

Not yet recruiting

Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapytype 2 diabetes

JPRN-UMIN000014968Tokyo Medical University Hospital Division of Diabetes,Metabolism and Endocrinology50

The effectiveness of oral hypoglycemic agents in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. -Multiple comparison, Dapagliflozin, Pioglitazone vs Glimepirideonalcoholic fatty liver disease patients with type 2 diabetes

JPRN-UMIN000021291Kawasaki Medical SchoolKawasaki Medical School Devision of Diabetes, Endocrinology and Metabolism90

Efficacy of Ipragliflozin in type 1 diabetic patientstype 1 diabetic patients

JPRN-UMIN000036038Ise Red Cross Hospital Department of Metabolic Diseases50

Study of effect of oral anti-diabetic medication on cognitive function in young and middle-aged type 2 diabetes mellitus patientsHealth Condition 1: E119- Type 2 diabetes mellitus without complications

CTRI/2020/02/023645Dr Vangaveti Sneha